These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37072054)

  • 61. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM
    Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Jan; 29(1):101-106. PubMed ID: 36028091
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
    Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
    Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Wogu AF; Wynia MK; Zane RD; Ginde AA
    medRxiv; 2022 Apr; ():. PubMed ID: 35411339
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland.
    Portmann L; de Kraker MEA; Fröhlich G; Thiabaud A; Roelens M; Schreiber PW; Troillet N; Iten A; Widmer A; Harbarth S; Sommerstein R;
    JAMA Netw Open; 2023 Feb; 6(2):e2255599. PubMed ID: 36790812
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
    Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
    Martínez-Baz I; Trobajo-Sanmartín C; Miqueleiz A; Casado I; Navascués A; Burgui C; Ezpeleta C; Castilla J; Guevara M; ;
    Euro Surveill; 2023 Feb; 28(5):. PubMed ID: 36729113
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The neutralizing response to SARS-CoV-2 Omicron variants BA.1 and BA.2 in COVID-19 patients and homologous and heterologous vaccinees.
    Dapporto F; Leonardi M; Trombetta CM; Semplici C; Piu P; Piccini G; Benincasa L; Marchi S; Andreano E; Lovreglio P; Buonvino N; Decaro N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Rappuoli R; Molesti E; Manenti A; Montomoli E
    Hum Vaccin Immunother; 2022 Nov; 18(6):2129196. PubMed ID: 36269939
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome.
    Lewnard JA; Hong V; Kim JS; Shaw SF; Lewin B; Takhar H; Tartof SY
    Nat Commun; 2023 Mar; 14(1):1407. PubMed ID: 36918548
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study.
    Ward IL; Bermingham C; Ayoubkhani D; Gethings OJ; Pouwels KB; Yates T; Khunti K; Hippisley-Cox J; Banerjee A; Walker AS; Nafilyan V
    BMJ; 2022 Aug; 378():e070695. PubMed ID: 35918098
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.
    Cao Y; Song W; Wang L; Liu P; Yue C; Jian F; Yu Y; Yisimayi A; Wang P; Wang Y; Zhu Q; Deng J; Fu W; Yu L; Zhang N; Wang J; Xiao T; An R; Wang J; Liu L; Yang S; Niu X; Gu Q; Shao F; Hao X; Meng B; Gupta RK; Jin R; Wang Y; Xie XS; Wang X
    Cell Host Microbe; 2022 Nov; 30(11):1527-1539.e5. PubMed ID: 36270286
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Taha TY; Chen IP; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Suryawanshi R; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Tabata T; Ott M; Doudna JA
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2200592119. PubMed ID: 35858386
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
    Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
    Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages.
    Xiang T; Wang J; Zheng X
    Virol Sin; 2022 Dec; 37(6):786-795. PubMed ID: 36427646
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
    McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
    Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
    Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
    BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England.
    Webster HH; Nyberg T; Sinnathamby MA; Aziz NA; Ferguson N; Seghezzo G; Blomquist PB; Bridgen J; Chand M; Groves N; Myers R; Hope R; Ashano E; Lopez-Bernal J; De Angelis D; Dabrera G; Presanis AM; Thelwall S
    Nat Commun; 2022 Oct; 13(1):6053. PubMed ID: 36229438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.